The t-test in the present study revealed a significant reduction of BUN, SCR, TNF-β1, VEGF, TIMP-1, and MMP-2 after treatment, and the use of axitinib plus tislelizumab resulted in greater reduction, indicating that axitinib combined with tislelizumab can improve renal function, probably because the interplay of these two plays a central role in reducing tumor blood supply via blocking the formation of neovascularization, so as to inhibit the proliferation and growth of VEGF, reduce the angiogenesis for tumor nutrients provision, and inhibit the occurrence and growth of tumor cells [20]. This evidence concerns the gene VEGFA and neoplasm.